Osteosarcoma is a disease in which the recent lack of progress in improving patient survival strongly suggests the need for novel treatment approaches. A panel of well characterized osteosarcoma patient derived xenografts with genetic changes recapitulating the disease, have been tested by our laboratory as part of the Pediatric Preclinical Testing Program. These efforts thus far have been highly successful in identifying several drugs which are currently being or about to be tested in osteosarcoma clinical trials conducted by the Children's Oncology Group - specifically eribulin and glembatumumab vedotin. Numerous additional osteosarcoma patient derived xenograft models have been developed potentially permitting expansion of the panel of tumors assessed. In this proposal exploration of using a more efficient approach to screen for drug activity in the established models may permit utilization of a broader panel of osteosarcoma patient derived xenografts. In this proposal eltrombopag will be explored for activity in the treatment of osteosarcoma based on promising in vitro data. Building on prior findings, eribulin will be tested for additive activiy with agents routinely used in the treatment of osteosarcoma including cisplatin, cyclophosphamide and etoposide. Finally, a novel ALK inhibitor that also has IGF-1R inhibitory activity, certinib, will be tested as a single agent and in combination with rapamycin for activityin the osteosarcoma patient derived xenografts. These results can be informative for future osteosarcoma clinical trials development as well as potentially identify novel agents that can be considered for clinical trials.

Public Health Relevance

Osteosarcoma the most common primary malignant bone tumor in children, adolescents and young adults, is a disease in which progress in improving survival has stagnated for the past three decades highlighting the need for novel therapies. In this proposal a highly informative and representative panel of osteosarcoma tumor samples obtained from patients and grown in immuno-deficient mice will be used to identify novel drugs and drug combinations that may be effective in clinical trials in osteosarcoma patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Smith, Malcolm M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Lowery, Caitlin D; Dowless, Michele; Renschler, Matthew et al. (2018) Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models. Clin Cancer Res :
Murphy, Brendan; Yin, Han; Maris, John M et al. (2016) Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Res 76:5798-5809
Attiyeh, Edward F; Maris, John M; Lock, Richard et al. (2016) Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatr Blood Cancer 63:276-86
Geller, David S; Morris, Jonathan; Revskaya, Ekaterina et al. (2016) Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R). Nucl Med Biol 43:812-817
Gorlick, Richard; Kolb, E Anders; Keir, Stephen T et al. (2016) Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63:443-50
Bishop, Michael W; Janeway, Katherine A; Gorlick, Richard (2016) Future directions in the treatment of osteosarcoma. Curr Opin Pediatr 28:26-33